Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial

• Published in: The Journal of urology Vol. 211; no. 6; pp. 743 - 753
• Main Authors: Djaladat, Hooman, Ghoreifi, Alireza, Tejura, Tapas, Miranda, Gus, Cai, Jie, Sheybaee Moghaddam, Farshad, Aldana, Ileana, Sotelo, Rene, Gill, Inderbir, Bhanvadia, Sumeet, Schuckman, Anne, Desai, Mihir, Aron, Monish, Daneshmand, Siamak, Duddalwar, Vinay
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Wolters Kluwer 01.06.2024
• Subjects: Aged; Cystectomy - adverse effects; Cystectomy - methods; Female; Follow-Up Studies; Humans; Incisional Hernia - prevention & control; Male; Middle Aged; Postoperative Complications - epidemiology; Postoperative Complications - etiology; Postoperative Complications - prevention & control; Prophylactic Surgical Procedures - methods; Surgical Mesh - adverse effects; Urinary Bladder Neoplasms - surgery; Urinary Diversion - methods; cystectomy; parastomal hernia; ileal conduit; prophylactic mesh; bladder cancer
• ISSN: 0022-5347; 1527-3792; 1527-3792
• DOI: 10.1097/JU.0000000000003902

Purpose:We assessed the effect of prophylactic biologic mesh on parastomal hernia (PSH) development in patients undergoing cystectomy and ileal conduit (IC).Materials and Methods:This phase 3, randomized, controlled trial (NCT02439060) included 146 patients who underwent cystectomy and IC at the University of Southern California between 2015 and 2021. Follow-ups were physical exam and CT every 4 to 6 months up to 2 years. Patients were randomized 1:1 to receive FlexHD prophylactic biological mesh using sublay intraperitoneal technique vs standard IC. The primary end point was time to radiological PSH, and secondary outcomes included clinical PSH with/without surgical intervention and mesh-related complications.Results:The 2 arms were similar in terms of baseline clinical features. All surgeries and mesh placements were performed without any intraoperative complications. Median operative time was 31 minutes longer in patients who received mesh, yet with no statistically significant difference (363 vs 332 minutes, P = .16). With a median follow-up of 24 months, radiological and clinical PSHs were detected in 37 (18 mesh recipients vs 19 controls) and 16 (8 subjects in both arms) patients, with a median time to radiological and clinical PSH of 8.3 and 15.5 months, respectively. No definite mesh-related adverse events were reported. Five patients (3 in the mesh and 2 in the control arm) required surgical PSH repair. Radiological PSH-free survival rates in the mesh and control groups were 74% vs 75% at 1 year and 69% vs 62% at 2 years.Conclusions:Implementation of biologic mesh at the time of IC construction is safe without significant protective effects within 2 years following surgery.